CLEC4C and systemic lupus erythematosus: For instance, even though SLE patients have a reduced number of BDCA-2-expressing pDCs, their IFN alpha production could be inhibited by a monoclonal antibody (mAb) targeting BDCA-2 (Blomberg et al, 2003).